

Thursday, September 25, 2003

COMPANY PRESS RELEASE

Transgenomic Inc. to Provide Additional Specialty Nucleic Acid Products to Geron Corporation

Continuing Support for Manufacture of Geron's Novel Cancer Therapeutic

OMAHA, Neb., Sept. 25, 2003 -- Transgenomic, Inc. (Nasdaq:TBIO) announced today that it has agreed to provide an additional supply of modified nucleic acid building block compounds to Geron Corporation (Nasdaq:GERN) for use in the synthesis of one of Geron's novel thio-phosphoramidate-based telomerase inhibitor anti-cancer drugs, GRN163L (formerly named GRN719).

Thio-phosphoramidate-based oligonucleotides represent a new class of synthetic nucleic acids that have demonstrated a number of potential advantages over earlier-generation oligonucleotide chemistries, including enhanced sequence-specific DNA and RNA binding activity, a high resistance to nuclease degradation and improved cellular uptake and biodistribution. These properties offer significant potential for the development of improved synthetic nucleic acid products used in research, therapeutic and diagnostic applications.

"We are pleased to have the opportunity to provide manufacturing support to Geron as they continue to develop their novel cancer therapeutics," said Collin D'Silva, Transgenomic's CEO. "Biopharmaceutical companies such as Geron have a need to adapt cutting-edge developments in nucleic acid chemistry for use in production-scale processes. Our nucleic acid chemistry expertise enables us to support the commercial adaptation of next-generation nucleic acid chemistries. Importantly, the extension of our non-exclusive licensing agreement with Geron in June 2003 allows us to manufacture phosphoramidate-based oligonucleotides and the chemical building blocks required for their synthesis, for use in diagnostic and therapeutic applications by other biotechnology, pharmaceutical and diagnostics companies to the mutual benefit of both Transgenomic and Geron."

About Transgenomic

Transgenomic provides versatile and innovative research tools and related consumable products to the life sciences industry for the synthesis, separation, analysis and purification of nucleic acids and a wide variety of nucleic acid-based specialty chemicals. Through its nucleic acids business segment, Transgenomic provides specialty chemicals, including advanced nucleic acid building blocks and associated reagents, used in applications such as genetic diagnostics and therapeutics. Manufacturing operations include a cGMP facility for the synthesis of oligonucleotides.

Transgenomic's biosystems segment offers its WAVE[®] Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. These systems have broad applicability to genetic research and molecular diagnostics. To date there have been approximately one thousand systems installed in over 30 countries around the world.

For more information about the innovative genomics research tools developed and marketed by Transgenomic, please visit the Company's Web site at www.transgenomic.com.

Forward-Looking Statement

Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to the development of improved synthetic nucleic acid products for use in research, therapeutic and diagnostic applications and facilitating the adaptation of cutting-edge developments in nucleic acid chemistry for use in production-scale processes. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic’s reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, Transgenomic claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release, and Transgenomic undertakes no duty to update this information, including any forward-looking statement, unless required by law.

###

For confirmation of release or further information, please contact:

Mitchell L. Murphy
Transgenomic, Inc.
402-452-5437
mmurphy@transgenomic.com

Rob Pogulis
Transgenomic, Inc.
845-782-9617
rpogulis@transgenomic.com